PHARMA & MEDICAL DEVICES

NITROSAMINES ANALYSIS
ON PHARMACEUTICAL PRODUCTS

Because you care about CONSUMERS’ HEALTH

MERIEUX NutriSciences
WHAT ARE NITROSAMINES?
Nitrosamines, or more correctly N-nitrosoamines, refer to any molecule containing the nitroso functional group. These molecules are of concern because nitrosamine impurities are probable human carcinogens, signifying that long-term exposure above certain levels may increase the risk of cancer development.

THE RISK EVALUATION PROCESS
On September 26th, 2019 the CMDh (Heads of Medicines Agencies) published the notice ‘Information on nitrosamines for marketing authorisation holders’ asking to all Marketing Authorization Holders (MAHs) of human medicinal products containing chemically synthesised active pharmaceutical ingredients to evaluate the risk of the presence of nitrosamine impurities in their products.
On September 2020, FDA published the Guidance for Industry Control of Nitrosamine Impurities in Human Drugs applicable to all chemical synthesised APIs and relative drug products recommending the following deadlines: March 2021 for Risk Assessment, and September 2023 for confirmatory testing and changes in drug applications.

STEP 1 RISK EVALUATION
MAHs should perform risk evaluation of their medicinal products containing chemically synthesised APIs.

STEP 2 CONFIRMATORY TESTING
Confirmatory tests should be carried out using validated and sensitive methods. MAHs should inform the competent authorities immediately if tests confirm the presence of a nitrosamine impurity irrespective of the amount detected.

STEP 3 CHANGES TO THE MARKETING AUTHORISATION
MAHs should apply for a variation in a timely manner to introduce any required changes, such as amendment of the manufacturing process or changes to product specifications.

CONFIRMATORY TESTING AND SUBMISSION OF VARIATIONS TO THE MARKETING AUTHORIZATION SHOULD BE CONCLUDED AT THE LATEST BY 26 SEPTEMBER 2022 FOR CHEMICAL MEDICINES AND 1 JULY 2023 FOR BIOLOGICAL MEDICINES.

ASSESSMENT & CONTROL OF MUTAGENIC IMPURITIES (ICH M7 GUIDELINE)
CONTROL LIMITS AND CONTROL STRATEGY TOXICOLOGY ASSESSMENT
Thanks to the long-standing experience, Mérieux NutriSciences has been developing various strategies and approaches for the determination of nitrosamines residues in different matrices through sophisticated mass spectrometry combined with a pool of experts. The GMP facility of Mérieux NutriSciences is equipped with all the analytical techniques used by the Official Medicines Control Laboratories (OMCLs).

### OUR CAPABILITIES

- **Dedicated Team & Lab** for analytical testing of NAC by: LC-HRMS or GC-HRMS with Orbitrap and/or TOF Technology; LC-MS/MS or GC-MS/MS (Triple Quadrupole Technology).

- **Confirmatory testing:** method development and validation, and GMP quantitative tests with validated methods on medium and high risk nitrosamine impurities (NI) on representative drug products (DPs)

- **Multiresidual analysis (standard set).**
  1. N-Nitrosodimethylamine (NDMA)
  2. N-Nitrosodiethylamine (NDEA)
  3. N-Nitrosomethylethylamine (NMEA)
  4. N-Nitrosoethylisopropylamine (NEIPA)
  5. N-Nitrosodiethylamine (NDEA)
  6. N-Nitrosodiphenylamine (NDPA)
  7. N-Nitrosodi-n-propylamine (NDPA)
  8. N-Nitrosodiisopropylamine (NDIPA)
  9. N-Nitroso-di-n-butylamine (NDBA)
  10. N-Nitrosomethylaniline (NMA)
  11. N-Nitroso-di-ethanolamine (NDELA)
  12. N-Nitroso-piperidine (NPIP)
  13. N-Nitroso-pyrrolidine (NPYR)
  14. N-Nitroso-morpholine (NMOR)

- **Targeted methods for almost 20 specific nitrosamines (on demand /R&D level) - not exhaustive list.**
  - N-nitrosodimethylamine (NDMA)
  - N-Nitrosodiethylamine (NDEA)
  - N-Nitrosomethylethylamine (NMEA)
  - N-Nitrosoethylisopropylamine (NEIPA)
  - N-Nitrosodiphenylamine (NDPA)
  - N-Nitrosodi-n-propylamine (NDPA)
  - N-Nitrosodiisopropylamine (NDIPA)
  - N-Nitroso-di-n-butylamine (NDBA)
  - N-Nitrosomethylaniline (NMA)
  - N-Nitroso-di-ethanolamine (NDELA)
  - N-Nitroso-piperidine (NPIP)
  - N-Nitroso-pyrrolidine (NPYR)
  - N-Nitroso-morpholine (NMOR)

- **Targeted screening by HRMS and/or MS/HRMS** (for detection of NI without available reference standards).

- **Nitrosation assay procedure - NAP test.** Residual qualitative test / trace analysis to identify a specific nitrosamine through the following analytical techniques: LC MS and/or MS/MS and/or HRMS and/or MS/HRMS and/or TOF and/or MS/TOF:
  - NAP TEST based on EMA Assessment Report
  - NAP TEST based on Mérieux NutriSciences Internal Procedure (verified/effective on most of amynes compounds)

- **Risk evaluation. GMP or non-GMP screening limit or quantitative tests** on raw materials of drug products supporting the Risk Assessment process in case of missing information: multiresidual NI analysis or single NI analysis (with or without reference standard).

- **New marketing authorisation and batch release.**
  - GMP multiresidual quantitative tests to demonstrate absence of NI before applying for new marketing authorisation
  - GMP QC tests for analytical batch release

- **Alerts management.**
  - Target method development & validation (rush service)
  - GMP QC tests on APIs and DPs on the market

- **Risk Assessment** with qualified partners.

### OUR EQUIPMENT

- LC-MS/HRMS - LC-MS/HRMS (Orbitrap and/or TOF Technology)
- GC-MS/MS - GC-MS/HRMS - GC/MS
MÉRIEUX NUTRISCIENCES OFFERS ITS SCIENTIFIC EXCELLENCE IN PHARMACEUTICAL, CHEMICAL, BIOCIDE, COSMETIC AND FOOD PRODUCTS TESTING AND CONSULTING TO ENSURE SUPPORT, OPTIMAL REACTIVITY AND FLEXIBILITY TO ITS CUSTOMERS ALL OVER THE WORLD.